Zacks: Brokerages Anticipate Antares Pharma Inc (NASDAQ:ATRS) Will Announce Quarterly Sales of $31.41 Million

Brokerages predict that Antares Pharma Inc (NASDAQ:ATRS) will report $31.41 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Antares Pharma’s earnings. The highest sales estimate is $33.20 million and the lowest is $30.20 million. Antares Pharma posted sales of $18.82 million in the same quarter last year, which would indicate a positive year over year growth rate of 66.9%. The firm is expected to issue its next earnings report on Thursday, February 27th.

On average, analysts expect that Antares Pharma will report full-year sales of $117.54 million for the current financial year, with estimates ranging from $116.30 million to $119.60 million. For the next year, analysts expect that the business will post sales of $155.50 million, with estimates ranging from $145.80 million to $164.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The business had revenue of $34.31 million for the quarter, compared to analysts’ expectations of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%.

Separately, BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Saturday. Three research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $4.05.

Shares of ATRS traded up $0.10 on Friday, reaching $4.16. The stock had a trading volume of 2,665,200 shares, compared to its average volume of 2,156,145. Antares Pharma has a twelve month low of $2.53 and a twelve month high of $4.22. The firm has a market capitalization of $662.70 million, a PE ratio of -104.00 and a beta of 0.80. The company has a quick ratio of 2.46, a current ratio of 2.95 and a debt-to-equity ratio of 1.00. The firm has a 50-day moving average of $3.49 and a 200 day moving average of $3.21.

Several institutional investors have recently made changes to their positions in the company. Monarch Partners Asset Management LLC grew its stake in shares of Antares Pharma by 51.1% during the third quarter. Monarch Partners Asset Management LLC now owns 167,820 shares of the specialty pharmaceutical company’s stock valued at $561,000 after acquiring an additional 56,770 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Antares Pharma during the third quarter valued at about $145,000. California Public Employees Retirement System grew its stake in shares of Antares Pharma by 21.3% during the third quarter. California Public Employees Retirement System now owns 255,971 shares of the specialty pharmaceutical company’s stock valued at $856,000 after acquiring an additional 44,976 shares in the last quarter. Sargent Investment Group LLC grew its stake in shares of Antares Pharma by 3.4% during the third quarter. Sargent Investment Group LLC now owns 3,324,890 shares of the specialty pharmaceutical company’s stock valued at $11,122,000 after acquiring an additional 108,315 shares in the last quarter. Finally, Cadence Capital Management LLC acquired a new stake in shares of Antares Pharma during the third quarter valued at about $102,000. Institutional investors own 38.33% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.